HighTower Advisors »

Summit Therapeutics shares owned by HighTower Advisors

Quarter-by-quarter ownership of Summit Therapeutics (SMMT) shares owned by HighTower Advisors from 13F filings

Historical chart of HighTower Advisors investment in Summit Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Summit Therapeutics held by HighTower Advisors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Summit Therapeutics by HighTower Advisors

Quarter filed Position value Share count Share price at filing
2023-12-31 $31k 12k 2.59

More positions owned by HighTower Advisors

Apple (AAPL)
Microsoft Corporation (MSFT)
Spdr S&p 500 Etf Tr Tr Unit (SPY)
Berkshire Hathaway Inc Del Cl A (BRK.A)
Ishares Tr Core S&p500 Etf (IVV)
Berkshire Hathaway Inc Del Cl B New (BRK.B)
Amazon (AMZN)
Vanguard Index Fds S&p 500 Etf Shs (VOO)
Johnson & Johnson (JNJ)
Alphabet Cap Stk Cl A (GOOGL)
Exxon Mobil Corporation (XOM)
JPMorgan Chase & Co. (JPM)
Invesco Qqq Tr Unit Ser 1 (QQQ)
Ishares Tr Core Msci Eafe (IEFA)
NVIDIA Corporation (NVDA)

View all positions for HighTower Advisors

Top funds holding Summit Therapeutics

Vanguard Group
Charles Schwab Investment Management
Steward Partners Investment Advisory
ALPS Advisors
Barclays
Bank of New York Mellon
Jpmorgan Chase & Co
Swiss National Bank
Goldman Sachs Group
UBS Group
Advisor Group Holdings
China Universal Asset Management
Rhumbline Advisers
CSS
Bank of America Corporation

View all funds holding Summit Therapeutics